After PSM, the 3-year DFS rate was analyzed by subgroups according to the menopause status (premenopausal or postmenopausal), tumor size (T1 or T2), lymph node metastasis (N0, N1, N2 or N3), clinical stage (II or IIIA), ER (positive or negative), PR (positive or negative), HER-2 (positive or negative), Ki-67 expression (< 20% or ≥ 20%), and histological grade (grade II or III). This evidence concerns the gene ERBB2 and neoplasm.